Document is current
Any future updates will be listed below
-
Authors
Li, Jia J. https://orcid.org/0000-0003-3676-5657
Vasciaveo, Alessandro https://orcid.org/0000-0003-0205-9869
Karagiannis, Dimitris
Sun, Zhen
Gretarsson, Kristjan H. https://orcid.org/0000-0002-9616-416X
Chen, Xiao
Ouerfelli, Ouathek https://orcid.org/0000-0002-7038-0219
Socciarelli, Fabio
Frankenstein, Ziv
Dong, Hanyang
Zou, Min
Yuan, Wei https://orcid.org/0000-0001-8004-1846
Yang, Guangli
Aizenman, Gabriel M.
Pannellini, Tania
Xu, Xinjing https://orcid.org/0000-0001-6677-711X
Beltran, Himisha https://orcid.org/0000-0003-3259-2226
Chen, Yu https://orcid.org/0000-0002-0171-3884
Gardner, Kevin https://orcid.org/0000-0001-8018-4353
Robinson, Brian D. https://orcid.org/0000-0001-5374-890X
de Bono, Johann
Gozani, Or https://orcid.org/0000-0002-1365-4463
Abate-Shen, Cory https://orcid.org/0000-0002-5021-0570
Rubin, Mark A.
Loda, Massimo https://orcid.org/0000-0001-9674-8379
Sawyers, Charles L. https://orcid.org/0000-0003-4955-6475
Califano, Andrea https://orcid.org/0000-0003-4742-3679
Lu, Chao https://orcid.org/0000-0003-0982-8122
Shen, Michael M. https://orcid.org/0000-0002-4042-1657
- License Information
-
More Information
Article History
Received: 1 July 2024
Accepted: 9 October 2025
First Online: 26 November 2025
Change Date: 16 January 2026
Change Type: Clarification
Change Details: Editor's note: Readers are alerted that concerns have been raised about the animal protocols. Appropriate editorial action will be taken once this matter is resolved.
Competing interests
: J.J.L., M.M.S., G.Y. and O.O. are inventors of patent applications related to this work. O.O. is an unpaid member of the Scientific Advisory Board of and owns shares of Angiogenex Therapeutics; he is an inventor on several patents, receives royalties from MSKCC, and is co-inventor of apalutamide. O.G. is a co-scientific founder, Board of Director member and stockholder of EpiCypher and Alternative Bio, and a co-scientific founder, consultant and stockholder of K36 Therapeutics. C.L.S. serves on the Board of Directors of Novartis, is a co-founder of ORIC Pharmaceuticals and co-inventor of enzalutamide and apalutamide. He is a science advisor to Arsenal, Beigene, Blueprint, Column Group, Foghorn, Housey Pharma, Nextech, KSQ, and PMV. A.C. is founder, equity holder, and consultant of DarwinHealth, a company that has licensed some of the algorithms used in this manuscript from Columbia University. Columbia University is also an equity holder in DarwinHealth. M.M.S. has served as a consultant for K36 Therapeutics. All other authors declare no competing interests.
